European Pharmaceutical Review

NOVEMBER 24, 2022

s Libtayo ® (cemiplimab) for adults with recurrent or metastatic cervical cancer and disease progression while on or after platinum-based chemotherapy. “Libtayo ® was the first programmed cell death protein (PD)-1 inhibitor to demonstrate significant improvements in survival compared to chemotherapy in a Phase III trial.

Chemotherapy 98

Chemotherapy Immunity Immunization Adverse Reactions 98

Pharmaceutical Technology

NOVEMBER 23, 2022

Libtayo is also indicated for treating progression of the disease on or following platinum-based chemotherapy. The trial enrolled 608 subjects in 14 countries, regardless of their PD-L1 expression status or histology and assessed Libtayo versus a chemotherapy of investigator's choice.

Adverse Reactions 52

Adverse Reactions Chemotherapy Immunity Immunization 52

LifeProNow

APRIL 19, 2023

The product is intended for use in adults and pediatric patients 12 years and older with blood cancers planned for umbilical cord blood transplantation following a myeloablative conditioning regimen (treatment such as radiation or chemotherapy). director of the FDA’s Center for Biologics Evaluation and Research.

Adverse Reactions 130

Adverse Reactions Chemotherapy Labelling Immunity 130

European Pharmaceutical Review

DECEMBER 27, 2023

Bridging therapy has been shown to correlate with an inferior response to CAR T-cell therapy due to both progression of the chemotherapy-refractory malignant disease during the manufacturing period and increased toxicity. After this incident CAR-related toxicity scales and guidelines were established to prevent adverse reactions.

Adverse Reactions 104

Adverse Reactions Immunity Immunization Medical Schools 104

pharmaphorum

JANUARY 26, 2022

It covers three phase 3 trials involving subjects with myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML), as well as ‘unfit’ AML patients who are unable to be treated with intensive treatment like high-dose chemotherapy.

Adverse Reactions 40

Adverse Reactions Chemotherapy Immunity Immunization 40

Express Pharma

JUNE 18, 2024

This is the first Phase 3 trial to statistically evaluate an anti-PD-1 immunotherapy plus chemotherapy combination in patients with pMMR and dMMR tumours as two independent cohorts,” said Dr Ramez N. Early identification and management of immune-mediated adverse reactions are essential to ensure safe use of KEYTRUDA.

Chemotherapy 59

Chemotherapy Adverse Reactions Immunity Immunization 59

The Thyroid Pharmacist

JULY 8, 2022

Selenium is vital to our body’s ability to convert T4 to T3, and has a balancing effect on our thyroid and immune health. There are many different types of selenoproteins that focus on different functions relating to thyroid and immune system support. Why such an impact on so many? This is how autoimmunity starts. percent felt worse.

Dosage 59

Dosage Immunity Immunization Diabetes 59